Press release
Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection
Company to provide comprehensive update in a presentation delivered today at the 43rd Annual J.P. Morgan Healthcare Conference Presentation outlines strength
About this update from Natera, Inc.
[{"type":"text","content":"\nCompany to provide comprehensive update in a presentation delivered today at the 43rd Annual J.P. Morgan Healthcare Conference\n\n\nPresentation outlines strength of existing oncology portfolio, along with pipeline of new products and data readouts\n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will provide an update to the investment community, today, at the 43rd annual J.P. Morgan Healthcare Conference. In addition to its previously announced preliminary financial results for the fourth quarter and year ended Dec. 31, 2024, the Company will also present details on its innovation roadmap for oncology.\n\n\n“Building on our strong preliminary financial results in 2024, we are poised for an exciting year with multiple potential catalysts,” said Steve Chapman, CEO. “Since launching the oncology business, we have focused on innovating the field of molecular residual disease testing to improve outcomes for patients. Today's announcement extends that commitment with promising new products and technologies in cancer testing.”\n\n\nLaunch of SignateraTM, Designed on Genome\n\n\nBuilding on the success of Natera’s exome-based Signatera assay, which has been extensively validated and widely adopted, Natera is pleased to introduce a new version of Signatera leveraging the genome. The test, which is now available for research and clinical use, enables bespoke assay design from a whole genome sequence (WGS) of a patient’s tumor.\n\n\nThe Signatera genome assay benefits from Natera’s patented multiplex polymerase chain reaction (PCR) next generation sequencing (NGS) methodology. The test detects down to low single-digit parts per million (PPM) and leverages Natera’s clinical data leadership from over 100 published studies on circulating tumor DNA (ctDNA) monitoring.\n\n\nTissue-free MRD\n\n\nNatera is pleased to unveil a new tissue-free molecular residual disease (MRD) capability, which is the result of growing expertise in methylation-based technologies and dovetails with its research in early cancer detection. The first launch is expected in mid-2025 in colorectal cancer (CRC), with additional tumor indications to follow. The preliminary data for the CRC assay will be presented at the American Society of Clinical Oncology (ASCO) GI symposium, which takes place Jan. 23-25, 20...